Author

S. B. Joseph

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Assay:DNA methylation· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:gene regulatory network inference· 1 Organism:non-human primate· 1 Organism:plant (other)· 1

Frequent Co-Authors

A. K. Chatterjee· 3 shared A. K. Gupta· 2 shared A. K. Woods· 2 shared C. W. McNamara· 2 shared D. M. Margolis· 2 shared M. A. Bakowski· 2 shared M. Moeser· 2 shared P. G. Schultz· 2 shared

Activity by Year

2019-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

A. K. Chatterjee

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A Prodrug Strategy to Reposition Atovaquone as a Long-Acting Injectable for Malaria Chemoprotection

A. K. Gupta, A. M. Eliasen, W. Andahazy, F. Zhou, K. Henson, V. Chi, A. K. Woods, S. B. Joseph, K. L. Kuhen, J. Wisler, H. Ramachandruni, J. Duffy, J. N. Burrows, E. Vadas, A. Slade, , A. K. Chatterjee

This paper develops three prodrug formulations of atovaquone for long-acting injectable malaria chemoprotection, showing two maintain therapeutic plasma levels for over 70 and 30 days in monkeys.

bioRxiv · Feb 8, 2024 · PreprintPharmacology & Toxicology

Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Covalent Warhead

N. G. R. D. Elshan, K. C. Wolff, L. Riva, A. K. Woods, G. Grabovyi, K. Wilson, A. Rahimi, J. Pedroarena, S. Ghorai, A. K. Gupta, A. Nazarian, F. Weiss, Y. Liu, W. Mazumdar, L. Song, , A. K. Chatterjee

This paper introduces CMX990, a potent SARS-CoV-2 3CL protease inhibitor with improved potency and clearance compared to nirmatrelvir, advancing to Phase 1 clinical trials.

bioRxiv · Oct 24, 2023Microbiology

A novel high throughput microwell outgrowth assay for HIV infected cells

A. Fenton, N. M. Archin, A.-M. W. Turner, S. B. Joseph, M. Moeser, D. M. Margolis, E. P. Browne

The paper introduces a high-throughput microwell outgrowth assay to quantify and characterize HIV-infected cells with high sensitivity and precision.

bioRxiv · Oct 2, 2023Microbiology

A Drug Repurposing Approach Reveals Targetable Epigenetic Pathways in Plasmodium vivax Hypnozoites

S. P. Maher, M. A. Bakowski, A. Vantaux, E. L. Flannery, C. Andolina, M. Gupta, Y. Antonova-Koch, M. Argomaniz, C.-M. Monica, C. Brice, A. T. Chao, A. K. Chatterjee, W. T. Cheng, E. Chuenchob, C. A. Cooper, , McNama

The paper identifies epigenetic inhibitors active against Plasmodium vivax hypnozoites through drug repurposing screens, showing epigenetic pathways are critical for hypnozoite quiescence.

bioRxiv · Jan 31, 2023 · PreprintCell Biology

The Replication-Competent HIV-1 Latent Reservoir is Primarily Established Near the Time of Therapy Initiation

M.-R. Abrahams, S. B. Joseph, N. Garrett, L. Tyers, M. Moeser, N. Archin, O. D. Council, D. Matten, S. Zhou, D. Doolabh, C. Anthony, N. Goonetilleke, S. A. Karim, D. M. Margolis, S. Kosakovsky Pond, , R. Swanstrom

The paper shows that most of the long-lived HIV-1 latent reservoir forms near the time of antiretroviral therapy initiation, not continuously during untreated infection.

bioRxiv · Jan 4, 2019Microbiology